Bell Investment Advisors Inc raised its holdings in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 77.0% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 1,131 shares of the company’s stock after acquiring an additional 492 shares during the period. Bell Investment Advisors Inc’s holdings in Johnson & Johnson were worth $200,000 at the end of the most recent reporting period.
Other large investors have also made changes to their positions in the company. Glassy Mountain Advisors Inc. acquired a new position in shares of Johnson & Johnson during the 4th quarter worth about $35,000. Retirement Financial Solutions LLC bought a new position in Johnson & Johnson in the 4th quarter valued at about $40,000. TD Capital Management LLC bought a new position in Johnson & Johnson in the 3rd quarter valued at about $48,000. VitalStone Financial LLC bought a new position in shares of Johnson & Johnson during the fourth quarter worth approximately $52,000. Finally, Iron Horse Wealth Management LLC increased its holdings in shares of Johnson & Johnson by 112.8% during the fourth quarter. Iron Horse Wealth Management LLC now owns 300 shares of the company’s stock worth $53,000 after purchasing an additional 159 shares during the period. Institutional investors own 67.94% of the company’s stock.
Analyst Upgrades and Downgrades
A number of brokerages recently issued reports on JNJ. Raymond James decreased their price objective on shares of Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating on the stock in a research note on Wednesday, April 19th. SVB Leerink cut their price target on shares of Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating on the stock in a report on Friday, January 20th. Credit Suisse Group boosted their target price on shares of Johnson & Johnson from $168.00 to $170.00 in a report on Friday, May 5th. Piper Sandler decreased their price target on shares of Johnson & Johnson from $55.00 to $52.00 in a research note on Monday, February 6th. Finally, UBS Group started coverage on shares of Johnson & Johnson in a research note on Tuesday, March 28th. They issued a “neutral” rating and a $164.00 price target for the company. Seven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $173.00.
Insider Buying and Selling
Johnson & Johnson Stock Down 0.1 %
JNJ opened at $159.34 on Wednesday. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.49. The stock has a market cap of $414.08 billion, a price-to-earnings ratio of 33.33, a PEG ratio of 2.74 and a beta of 0.53. Johnson & Johnson has a twelve month low of $150.11 and a twelve month high of $183.35. The company’s 50-day moving average price is $159.29 and its two-hundred day moving average price is $166.49.
Johnson & Johnson (NYSE:JNJ – Get Rating) last announced its quarterly earnings results on Tuesday, April 18th. The company reported $2.68 EPS for the quarter, beating analysts’ consensus estimates of $2.51 by $0.17. The company had revenue of $24.75 billion for the quarter, compared to analysts’ expectations of $23.61 billion. Johnson & Johnson had a net margin of 13.22% and a return on equity of 36.13%. Johnson & Johnson’s revenue was up 5.6% compared to the same quarter last year. During the same period in the prior year, the company posted $2.67 EPS. As a group, equities analysts expect that Johnson & Johnson will post 10.66 earnings per share for the current year.
Johnson & Johnson Increases Dividend
The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 6th. Investors of record on Tuesday, May 23rd will be issued a dividend of $1.19 per share. This represents a $4.76 dividend on an annualized basis and a yield of 2.99%. The ex-dividend date of this dividend is Monday, May 22nd. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.13. Johnson & Johnson’s dividend payout ratio is 94.56%.
About Johnson & Johnson
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Featured Stories
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- How to Calculate Stock Growth
- 7 Best Retail Stocks to Invest in
- 3 Home Improvement Stocks to Renovate Your Portfolio
- Beam Global Shines Brightly in the EV Infrastructure Space
- Canoo Bottoms As Production Ramp Gets CloserÂ
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
